


# BAHCET DISEASE

- *Created by :*
- *1.DUAA QATAWEN*
- *2. ABDALLAH ALBRAIZAT*
- *3.OHOUD ALNSERAT*

## Symptoms of Behçet's




# DEFINITION :

- Behcet disease (BD) is a chronic relapsing inflammatory vascular disease of unknown etiology
- Named after Hulusi Behcet, Turkish dermatologist found this disease characterized by a triad of recurrent oral ulcers, genital ulcers & uveitis

# Triad of bahcet disease

## Behçet syndrome



Relapsing uveitis




Recurring genital ulcers



Recurring oral ulcers

### Painful Ulcers



Necrotic center

Red rim

- 
- Other clinical features include skin lesions, arthritis, gastrointestinal involvement, neurologic disease, and vascular disease.
  - Mucocutaneous and ocular disease are more active in early years, while the vascular and neurologic disease tends to come later on
  - Ocular disease has the greatest morbidity, followed by vascular disease generally
- 

- Patients are most commonly from the Middle East, the Mediterranean region, and the Far East; it is most prevalent in Turkey, with a prevalence of 1 in 250 adults.
- It is relatively rare before the late teens and after age 50. The commonest age (20-40 years).
- Males and females are equally affected; however, males frequently have more severe disease and poorer outcomes.
- Some manifestations may show regional differences; for example, gastrointestinal involvement, rare in Turkey, is more common in Japan and is seen in ~30% of patients in the United States.

# Pathogenesis

---

Pathogenesis of BD is not completely clear.

---

Genetic, trigger factors, and immunological abnormalities are reported.

---

HLA-B\* 51 & HLA-B5101 & HLA-B5103 are common risk factor in BD

---

Reduced IL-10 (anti-inflammatory cytokine)

---

The pathogenesis includes autoimmunity, auto-inflammation & thrombophilia.


# Infectious triggers:



HSV, strept, Staph & E coli have high affinity for HLA-B51 stimulate innate immunity, NK cells, gama delta T cells & neutrophils



Excessive production of pro-inflammatory cytokines (inflammation, stimulation of T cells, tissue destruction, endothelial dysfunction & thrombus formation



# 1990 International Study Group (ISG) clinical criteria for Behçet's Disease (BD):

- **Recurrent oral ulcerations (97-99%) at least 3 times/year plus 2 of the following:**
- Recurrent genital ulceration (80%)
- Skin lesions 80% (papulopustular lesions acneiform nodules, pseudo-folliculitis, EN)
- Eye lesions 50% (uveitis, vitritis, retinitis)
- Positive pathergy test (50%)

international criteria  
for behcet's disease (icbd), Scoring 4  
is diagnostic :

Sign/symptom	Points
Ocular lesions	2
Genital aphthosis	2
Oral aphthosis	2
Skin lesions	1
Neurological manifestations	1
Vascular manifestations	1
Positive pathergy test*	1*


# Pathergy test :



**Pathergy test**  
What is the technique and its role in diagnosis?

# Pathergy test


- Site: Commonly volar aspect of forearm.
- Intradermal injection of 0.1 ml isotonic salt solution using 20 G needle without prior disinfection of the injection site.
- 3-5 mm intradermally at an angle of 45 degree.
- Reading – after 24-48 hours
- +ve result- Erythematous papule or pustule (>2 mm) at prick site.



Positive result :

## Behcet's Disease

Pathergy Test (pustule Formation)



- Pathergy test is not pathognomonic.
- +ve results can also occur in patients with,
  - Pyoderma gangrenosum
  - Rheumatoid arthritis
  - Crohn disease
  - Genital herpes infection




# CLINICAL PRESENTATION





# Oral Ulcers (97-99%)

- Painful oral ulcers
- Initial symptom (mostly) or seen at some time during the clinical course.
- Gingiva, tongue, buccal & labial mucosa.
- Round, with sharp, erythematous border & covered with yellowish pseudomembrane
- They last around 10 days without scarring but recur unless treated





## Genital ulcers (75%).

- On the scrotum and penis in males and on the vulva in females.
- Painful and morphologically similar to the oral ulcers but they are larger, deeper, with irregular margin and take longer to heal than oral ulcers and usually leave scars.





# Cutaneous manifestations (75%)

- Papulopustular acneiform lesions
- Pseudo-folliculitis,
- Erythema nodosum like lesion.
- Cutaneous small vessel vasculitis with ulcers.
- Pyoderma gangrenosum
- Hypersensitive skin (+ ve. Pathergy test)

**papulopustular  
acneiform lesions**



**Pseudo-folliculitis**



# Erythema nodosum



# Pyoderma gangrenosum






## Inflammatory eye disease (50%)

- More common in males of young age.
- Occurs latter on within 2-3 years of onset
- Better prognosis with later onset.
- Ocular Behcet's may be only presentation
- Poor prognosis: male, posterior involvement, frequent attacks (>3 per year), strong vitreous opacity, and macular edema
- It is most commonly a bilateral panuveitis
- A hypopyon, seen in ~10% of patients with eye disease, is an intense inflammation in the anterior chamber and is quite specific for Behçet syndrome.

**panuveitis**



**hypopyon**





## Vascular involvement (40%)

- Venous involvement as DVT or superficial thrombophlebitis is more common than arterial involvement (about 30%)
- Showering of pulmonary emboli is rare?
- The superior and inferior vena cava could be obstructed producing a dramatic clinical picture.
- Hepatic vein (Budd-Chiari syndrome)



DVT

superficial thrombophlebitis





# Pulmonary vasculitis

- Pulmonary artery thrombosis,
- Pulmonary artery hypertension.
- Pulmonary artery aneurysms (common complication, It is fatal complication manifests as hemoptysis, cough, chest pain, or dyspnea and needs urgent management).



## Arterial involvement

- Occurs in 5% of patients,
- More in males
- Presents as arterial aneurysm or thrombosis,
- Aorta and main branches could be affected



## Neuro-Behcet disease (NBD).

- Like eye disease, is commoner in males and seen in (5-10%) of patients.
- Increased frequency of HLA-B5103
- Develop latter on, few years after the onset of other systemic features of BD
- It is either parenchymal or nonparenchymal
- Parenchymal involvement usually affects the telencephalic-diencephalic junction, brainstem, and spinal cord.
- Patients may present with a subacute onset of severe headache, cranial nerve palsy, dysarthria, ataxia, and hemiparesis.



## Joint affection

- Non-deforming arthritis or arthralgias are seen in a 50% of patients
- it is usually a mono- or oligoarthritis in the lower extremities mainly knees & ankles.






# Gastrointestinal


- Abdominal pain; ulcerative lesions at any level but mainly ileocaecal region;
- Clinical differentiation from IBD is difficult.
- it is difficult to distinguish Behçet syndrome from Crohn's disease unless extraintestinal lesions are present.

# Cardiac manifestations (5-10%):

- Coronary vasculitis and thrombosis,
  - Pericarditis, myocarditis, endocarditis e granulomatous changes or fibrosis, and diastolic dysfunction
- 
- Nephrotic syndrome.
  - Epididymitis, urethritis & neurogenic bladder
  - Materno-fetal problems (hypercoagulability)

investigations



- Complete blood count: neutrophilia
  - C –reactive protein- raised
  - ESR-raised
  - HLA-B51 test-positive
  - Skin Biopsy
  - CSF analysis
  - MRI/CT Scan
  - Chest X ray
  - Endoscopy
  - Pathergy test
- 

TREATMENT

- Treatment is guided by type and severity of involvement, with the goal of preventing long-term damage.
- Most new manifestations present within the first 5 years, and for most patients, the natural course is one of diminishing symptoms culminating in potential remission, frequently not requiring ongoing treatment with medications.
- Patient characteristics, such as being young and male, need to be kept in mind as these patients tend to have a worse prognosis.
- For most patients, tapering and/or stopping their medications in 2–3 years after the symptoms have improved should be attempted.

# Inflammatory eye disease

- glucocorticoids and longer-term treatment with an immunosuppressant, azathioprine is usually the preferred agent.
- Infliximab, adalimumab, or cyclosporine can also be used, in combination with systemic glucocorticoids and azathioprine, for control of disease activity
- Glucocorticoids can be tapered in many patients after active disease has been controlled, whereas immunosuppressants are generally continued for at least 2 years

# Oral ulcers

- can be managed with topical glucocorticoids and on an as-needed basis if mild
- Lesions resistant to local measures may require systemic treatment with colchicine, oral glucocorticoids, immunosuppressants such as apremilast, azathioprine, or a tumor necrosis factor- $\alpha$  inhibitor such as infliximab
- Patients may need a combination of medications, at least initially, to control disease activity.
- A similar treatment approach can be used for genital ulcers and other mucocutaneous manifestations.

- **Gastrointestinal involvement:** is treated with a glucocorticoid plus an immunosuppressant such as azathioprine alone or in combination with infliximab
- **Venous thrombotic events:** are treated by controlling systemic inflammation with immunosuppressive medications (usually azathioprine or, for more severe cases, cyclophosphamide), rather than using anticoagulants.
- **For central nervous system involvement:** the combination of azathioprine and a tumor necrosis factor inhibitor is usually the first choice.



عَلَى هَذِهِ الْأَرْضِ مَا يَسْتَحِقُّ الْحَيَاةُ